Inhibitors of pro-HGF that we developed blocked the pro-survival activity of fibroblasts, indicating that dual inhibition of MET and HGF is required to overcome resistance to MET-targeted therapy in MET-amplified NSCLC. Here, MET is linked to non-small cell lung carcinoma.